Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - chloramphenicol, quantity: 10 mg/g - eye ointment - excipient ingredients: wool fat; liquid paraffin; white soft paraffin - indications as at 29 january 2001: for the treatment of bacterial conjunctivitis and other superficial ocular infections caused by chloramphenicol-sensitive organisms.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - mometasone furoate, quantity: 1 mg/g - cream - excipient ingredients: purified water; phosphoric acid; aluminium starch octenylsuccinate; white beeswax; hydrogenated soy phosphatidylcholine; hexylene glycol; white soft paraffin; titanium dioxide - the short term up to four (4) continuous weeks relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 10 mg/ml - injection, suspension - excipient ingredients: carmellose sodium; polysorbate 80; benzyl alcohol; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - intra-articular: kenacort-a 10 injection (sterile triamcinolone acetonide suspension usp) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute non-specific tenosynovitis, post-traumatic osteoarthritis. intradermal: intralesional administration of kenacort-a 10 injection is indicated for the treatment of keloids, discoid lupus erythermatous, necrobiosis lipoidica diabeticorum, alopecia areata and localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus ( neurodermatitis), kenacort-a 10 injection also may be useful in cystic tumours of an aponeurosis or tendon ( ganglia).

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - dexamfetamine sulfate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - salbutamol sulfate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - salbutamol sulfate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg (equivalent: prednisolone, qty 5 mg) - suppository, moulded - excipient ingredients: hard fat - indications as at 01 jan 1991 : predsol suppositories are indicated for the treatment of haemorrhagic and granular proctitis, post-radiation proctitis and rectal complication of crohn's disease.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 40 mg/ml - injection, suspension - excipient ingredients: benzyl alcohol; sodium chloride; polysorbate 80; carmellose sodium; water for injections; sodium hydroxide; hydrochloric acid - intramuscular: the intramuscular administration of kenacort-a 40 (sterile triamcinolone acetonide suspension usp) is indicated for systemic corticosteroid therapy in such conditions as allergic diseases, dermatoses, or generalised rheumatoid arthritis and other connective tissue disorders. intramuscular administration is particularly valuable in such conditions where oral corticosteroid therapy is not feasible. intra-articular: kenacort-a 40 injection is indicated for intra-articular or intrasynovial administration and for injections into tendon sheaths as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; post-traumatic osteoarthritis.